A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

NCT04534283 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

OTHER

Sponsor class

Stopped Lack of efficacy.

Conditions

Cancer
Cancer Metastatic
BRAF V600E
MEK1 Gene Mutation
MEK2 Gene Mutation
ERK Mutation
RAF1 Gene Mutation

Interventions

DRUG: Abemaciclib
DRUG: LY3214996

Sponsor

Anita Turk

Collaborators

[object Object]